Integra LifeSciences (IART) Tops Q4 EPS by 1c; Offers 2022 Guidance

Integra LifeSciences (NASDAQ: IART) reported Q4 EPS of $0.84, $0.01 better than the analyst estimate of $0.83. Revenue for the quarter came in at $405.5 million versus the consensus estimate of $403.4 million.

GUIDANCE:

Integra LifeSciences sees FY2022 EPS of $3.27-$3.35, versus the consensus of $3.42. Integra LifeSciences sees FY2022 revenue of $1.58-1.6 billion, versus the consensus of $1.63 billion.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.

You May Also Be Interested In

• Argus Upgrades Integra LifeSciences (IART) to Buy, 'Valuations are still low'
• SpaceX receives Baa1 rating from Moody's with stable outlook
• John Wiley & Sons, Inc. (WLYB) Tops Q4 EPS by 12c; Offers Outlook